Joinn Laboratories (China) Co (SHSE:603127) Cash Flow for Dividends: ¥0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603127 Joinn Laboratories (China) Co Ltd SHSE:603127
78 GF Score
Price ¥41.54
GF Value ¥17.43
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Joinn Laboratories (China) Co Cash Flow for Dividends?

Joinn Laboratories (China) Co SHSE:603127 +3.72% 78 Cash Flow for Dividends is ¥0 Mil as of Mar. 2026. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.43 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Joinn Laboratories (China) Co's cash flow for dividends for the three months ended in Mar. 2026 was ¥0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Joinn Laboratories (China) Co's annual payment of dividends declined from Dec. 2023 (¥-214 Mil) to Dec. 2024 (¥-120 Mil) and declined from Dec. 2024 (¥-120 Mil) to Dec. 2025 (¥-22 Mil).

Joinn Laboratories (China) Co Cash Flow for Dividends Related Terms

Joinn Laboratories (China) Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Joinn Laboratories (China) Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co Cash Flow for Dividends Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -95.27 -137.72 -214.33 -119.63 -22.39

Joinn Laboratories (China) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:603127
78GF Score
Joinn Laboratories (China) Co Ltd SHSE:603127
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Joinn Laboratories (China) Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ¥0 Mil mean?
Joinn Laboratories (China) Co (SHSE:603127) has a Cash Flow for Dividends of ¥0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Joinn Laboratories (China) Co and its competitors.
Is Joinn Laboratories (China) Co's Cash Flow for Dividends too high?
Joinn Laboratories (China) Co's current Cash Flow for Dividends is ¥0 Mil. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Cash Flow for Dividends compare to TMO and DHR?
Joinn Laboratories (China) Co's Cash Flow for Dividends of ¥0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Medical Diagnostics & Research company?
A good Cash Flow for Dividends depends on the Medical Diagnostics & Research industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Cash Flow for Dividends is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.43, compared to a current price of ¥41.54 — trading 138.3% above its estimated fair value. The current Cash Flow for Dividends is ¥0 Mil. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Cash Flow for Dividends is ¥0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?

Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued. The current stock price of ¥41.54 is trading 138.3% above its estimated GF Value™ of ¥17.43. GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.

Key valuation signals for SHSE:603127:

  • Cash Flow for Dividends: ¥0 Mil
  • GF Value™: ¥17.43 vs. price of ¥41.54 (138.3% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Joinn Laboratories (China) Co Business Description

Other Exchanges 06127:Hong Kong
Address A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score

Get the complete analysis for SHSE:603127

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥41.54
Price
¥17.43
GF Value